Intervention Protocol

You have free access to this content

Zaleplon for insomnia

  1. Susanne Rösner1,*,
  2. Michael Soyka2,
  3. Göran Hajak3,
  4. Renate Wehrle4,
  5. Christian Englbrecht2

Editorial Group: Cochrane Common Mental Disorders Group

Published Online: 26 AUG 2013

DOI: 10.1002/14651858.CD010702

How to Cite

Rösner S, Soyka M, Hajak G, Wehrle R, Englbrecht C. Zaleplon for insomnia (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010702. DOI: 10.1002/14651858.CD010702.

Author Information

  1. 1

    Forel Klinik, Ellikon an der Thur, Switzerland

  2. 2

    University of Munich, Psychiatric Hospital, Munich, Germany

  3. 3

    Psychiatric Hospital, Psychiatry, Regensburg, Bavaria, Germany

  4. 4

    EasyCap, Herrsching, Germany

*Susanne Rösner, Forel Klinik, Islikonerstrasse 5, Ellikon an der Thur, 8548, Switzerland.

Publication History

  1. Publication Status: New
  2. Published Online: 26 AUG 2013



Additional references

American Academy of Sleep Medicine 2005
  • American Academy of Sleep Medicine. International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd Edition. Westchester, IL: American Academy of Sleep Medicine, 2005.
American Psychiatric Association 2000
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth, Text Revision (DSM-IV-TR). Washington DC: American Psychiatric Press, 2000:553-7.
Angst 1989
  • Angst J, Vollrath M, Koch R, Dobler-Mikola A. The Zurich Study. VII. Insomnia: symptoms, classification and prevalence. European Archives of Psychiatry and Neurological Sciences 1989;238(5-6):285-93.
Ballenger 2000
  • Ballenger JC. Benzodiazepine receptor agonists and antagonists. In: Sadock VA, Sadock BJ, Kaplan HI editor(s). Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 7th Edition. Philadelphia: Lippincott Williams & Wilkins, 2000.
Barbera 2005
Barbone 1998
Bastien 2004
  • Bastien CH, Vallières A, Morin CM. Precipitating factors of insomnia. Behavioral Sleep Medicine 2004;2(1):50-62.
Bateson 2004
Bolton 2008
  • Bolton JM, Metge C, Lix L, Prior H, Sareen J, Leslie WD. Fracture risk from psychotropic medications: a population-based analysis. Journal of Clinical Psychopharmacology 2008;28(4):384-91.
Buscemi 2007
  • Buscemi N, Vandermeer B, Friesen C, Bialy L, Tubman M, Ospina M, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. Journal of General Internal Medicine 2007;22(9):1335-50.
Deeks 2008
  • Deeks J, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008:243-93.
Delahaye 1990
  • Delahaye C, Ferrand B, Pieddeloup C, Musch B. Post marketing surveillance of zopiclone: interim analysis on the first 10,000 cases in a clinical study in general practice. International Clinical Psychopharmacology 1990;5 Suppl(2):131-8.
DerSimonian 1986
Dolder 2007
Drover 2000
  • Drover D, Lemmens H, Naidu S, Cevallos W, Darwish M, Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clinical Therapeutics 2000;22(12):1443-61.
Drover 2004
Dündar 2004a
Dündar 2004b
  • Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technology Assessment 2004;8(24):iii-x, 1-125.
Egger 1997
Erman 2005
  • Erman MK. Therapeutic options in the treatment of insomnia. Journal of Clinical Psychiatry 2005;66(9):18-23.
Espie 2002
Falcón 2009
Fernández-Mendoza 2010
  • Fernández-Mendoza J, Vela-Bueno A, Vgontzas AN, Ramos-Platón MJ, Olavarrieta-Bernardino S, Bixler EO, et al. Cognitive-emotional hyperarousal as a premorbid characteristic of individuals vulnerable to insomnia. Psychosomatic Medicine 2010;72(4):370-403.
Follesa 2002
  • Follesa P, Mancuso L, Biggio F, Cagetti E, Franco M, Trapani G, et al. Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology 2002;42(2):191-8.
Greenblatt 1981
  • Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines. A summary of pharmacokinetic properties. British Journal of Clinical Pharmacology 1981;11(Suppl 1):11-6.
Hajak 1997
  • Hajak G, Muller-Popkes K, Riemann D, Mayer G, Lauer C. Psychological, psychotherapeutic and other non-pharmacologic forms of therapy in treatment of insomnia. Fortschritte der Neurologie-Psychiatrie 1997;65(3):133-44.
Hajak 2003
Hausken 2009
  • Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG. Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. European Journal of Clinical Pharmacology 2009;65(3):295-01.
Higgins 2003
Higgins 2008
  • Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons, 2008:243-96.
Hoffmann 2009
Johnson 2001
Lader 1999
  • Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they justified?. European Neuropsychopharmacology 1999;9(Suppl 6):399-405.
Leshner 2005
  • Leshner A. NIH State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consensus and State-of-the-Science Statements. 2005; Vol. 22:1-30.
Lieberman 2007
  • Lieberman JA. Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Primary Care Companion to the Journal of Clinical Psychiatry 2007;9(1):25-31.
Light 1984
  • Light RJ, Pillemer BD. The Science of Reviewing Research. Cambridge (MA): Harvard University Press, 1984.
Lingford-Hughes 2002
  • Lingford-Hughes A, Hume SP, Feeney A, Hirani E, Osman S, Cunningham VJ, et al. Imaging the GABA-benzodiazepine receptor subtype containing the alpha 5-subunit in vivo with (11C)Ro15 4513 positron emission tomography. Journal of Cerebral Blood Flow and Metabolism 2002;22:878–88.
Mantel 1959
Moher 2009
Monti 2007
  • Monti JM, Pandi-Perumal SR. Eszopiclone: its use in the treatment of insomnia. Neuropsychiatric Disease and Treatment 2007;3(4):441-53.
Montplaisir 2003
Moore 2000
  • Moore EC. Zaleplon (Sonata®, Wyeth Ayerst): A new, non-benzodiazepine sedative/hypnotic. Journal of the Pharmacy Society of Wisconsin 2000; Vol. September/October:33-8.
Morin 2006
  • Morin CM, LeBlanc M, Daley M, Grégoire JP, Mérette C. Epidemiology of insomnia: Prevalence, self-help treatments, consultations, and determinants of help-seeking behaviours. Sleep Medicine 2006;7:123-30.
Najib 2006
NHS Prescribing Service 2010
  • National Prescribing Service. Addressing hypnotic medicines use in primary care. 2010.
Nutt 2010
Ohayon 2001
Ohayon 2002
Ohayon 2009
  • Ohayon MM, Reynolds CF 3rd. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD). Sleep Medicine 2009;10(9):952-60.
Perlis 2007
Ramakrishnan 2007
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Riemann 2007
Riemann 2009
Rosekind 2010
Roth 2003
  • Roth T, Roehrs T. Insomnia: epidemiology, characteristics, and consequences. Clinical Cornerstone 2003;5(3):5-15.
Roth 2009
Royal College of Psychiatrists 1997
  • Royal College of Psychiatrists. Benzodiazepines: risks, benefits or dependence. A re-evaluation. Council Report. London, 1997; Vol. CR59.
Rudolph 2011
Rush 1999
Rösner 2013a
  • Rösner S, Soyka M, Hajak G, Wehrle R. Zolpidem for insomnia. Cochrane Database of Systematic Reviews 2013, Issue 8.
Rösner 2013b
  • Rösner S, Soyka M, Hajak G, Wehrle R. Zopiclone for insomnia. Cochrane Database of Systematic Reviews 2013, Issue 8.
Rösner 2013c
  • Rösner S, Soyka M, Hajak G, Wehrle R. Eszopiclone for insomnia. Cochrane Database of Systematic Reviews 2013, Issue 8.
Rücker 2008
Schutte-Rodin 2008
  • Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. Journal of Clinical Sleep Medicine 2008;4(5):487-504.
Sieghart 2006
Siriwardena 2008
  • Siriwardena AN, Qureshi MZ, Dyas JV, Middleton H, Orner R. Magic bullets for insomnia? Patients' use and experiences of newer (Z drugs) versus older (benzodiazepine) hypnotics for sleep problems in primary care. British Journal of General Practice 2008;58(551):417-22.
Soyka 2000
Spielman 1991
Woolcott 2009
  • Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Archives of Internal Medicine 2009;169(21):1952-60.
World Health Organization 1992
  • World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: The World Health Organization, 1992.
Zammit 1999
  • Zammit GK, Weiner J, Damato N, Sillup GP, McMillan CA. Quality of life in people with insomnia. Sleep 1999;22(2):379-85.
Zammit 2009